Pharmaceuticals firm SUVEN Life Sciences declares Q3FY22 result: Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company. Clinical development pipeline: SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 3 study for new indication on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by end of the year 2024. Expected site activation by end of March 2022 and expected patient enrollment during the quarter April – June 2022. SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by FY2023. 109 patients randomized, 82 completed of the total expected 195 patients (including 18 replacements). SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2 SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2 Since last reporting period, the Company has been granted 19 patents for its innovative drug discovery covering ARIPO, Brazil, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, Singapore, Sri Lanka, South Africa and USA. Result PDF
Highlights Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company. Clinical development pipeline: SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 3 study on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by the year end 2024 SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by the year end 2022 SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2 SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2 Since last reporting period, the Company has been granted 13 patents for its innovative drug discovery covering ARIPO, China, Eurarisia, Hong Kong, Macao, South Africa, Sri Lanka, and USA. Result PDF